Loading
companiesCompany
Dendreon
Dendreon makes sipuleucel-T (Provenge), the first autologous cellular immunotherapy approved for cancer, for metastatic prostate cancer; the company went bankrupt in 2014 and has been owned by China's Sanpower group since 2017.
Also called: Dendreon PharmaceuticalsDendreon Corporation
Overview
Dendreon, now based in Seal Beach, California, developed sipuleucel-T (Provenge), an autologous cellular immunotherapy in which a patient's own antigen-presenting cells are activated against prostatic acid phosphatase and reinfused; it was approved by the FDA in 2010 for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after the IMPACT trial. High cost and slow uptake led the company into bankruptcy in 2014; Valeant bought the assets in 2015 and sold the business to the Sanpower Group in 2017, which continues to market Provenge in the United States. OnCo records it as a registry sponsor of phase 3 cancer trials.
Headquarters
Seal Beach, CA, US
Scorecard
All companies#241of 1244 companies, score 21
- approved products +6
- modalities +2
- regions +2
- registry trials +11
1 approved, 0 in phase 3, 0 earlier, 0 targets, 29 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
ApprovedAutologous cellular immunotherapy (antigen-presenting cell vaccine)
Sipuleucel-T · Provenge
Sipuleucel-T was the first therapeutic cancer vaccine approved (2010): it lengthened survival in metastatic prostate cancer by about four months without shrinking tumours or lowering PSA.
Similar pages
- TargetProstatic acid phosphatase (ACP3, PAP)
Shares Sipuleucel-T, Prostate cancer.
- Key paperSipuleucel-T immunotherapy for castration-resistant prostate cancer
Shares Sipuleucel-T, Prostate cancer.
- TreatmentPROSTVAC
Shares IMPACT (sipuleucel-T), Prostate cancer.
- TrialPROSPECT
Shares IMPACT (sipuleucel-T), Prostate cancer.
- TrialCA184-043
Shares IMPACT (sipuleucel-T), Prostate cancer.
- TechnologyDendritic cell vaccines
Shares IMPACT (sipuleucel-T), Sipuleucel-T, Prostate cancer.
- TermCancer vaccines and oncolytic viruses
Shares Sipuleucel-T, Prostate cancer.
- TermProstate cancer drugs in England: what NICE recommends, and what it refuses
Shares Sipuleucel-T, Prostate cancer.
cancers
fronts
drugs
ApprovedAutologous cellular immunotherapy (antigen-presenting cell vaccine)
Sipuleucel-T · Provenge